Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
11.60
-0.25 (-2.11%)
At close: May 17, 2024, 4:00 PM
11.02
-0.58 (-5.00%)
After-hours: May 17, 2024, 6:04 PM EDT

Y-mAbs Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2016
Revenue
84.8265.2734.920.750
Upgrade
Revenue Growth (YoY)
29.96%87.03%68.18%--
Upgrade
Cost of Revenue
11.427.572.512.20
Upgrade
Gross Profit
73.457.732.3818.550
Upgrade
Selling, General & Admin
44.8660.9454.5744.7919.51
Upgrade
Research & Development
54.2291.5793.2593.763.49
Upgrade
Operating Expenses
99.08152.51147.82138.4883
Upgrade
Operating Income
-25.67-94.81-115.43-119.94-83
Upgrade
Interest Expense / Income
-4.810.761.85-0.6-1.98
Upgrade
Other Expense / Income
---62.01--
Upgrade
Pretax Income
-20.87-95.57-55.28-119.34-81.03
Upgrade
Income Tax
0.560000
Upgrade
Net Income
-21.43-95.57-55.28-119.34-81.03
Upgrade
Shares Outstanding (Basic)
4444434035
Upgrade
Shares Outstanding (Diluted)
4444434035
Upgrade
Shares Change
-0.13%1.21%7.64%14.03%22.28%
Upgrade
EPS (Basic)
-0.49-2.19-1.28-2.97-2.30
Upgrade
EPS (Diluted)
-0.49-2.19-1.28-2.97-2.30
Upgrade
Free Cash Flow
-27.23-75.92-41.21-91.41-75.46
Upgrade
Free Cash Flow Per Share
-0.62-1.74-0.95-2.28-2.15
Upgrade
Gross Margin
86.54%88.41%92.80%89.38%-
Upgrade
Operating Margin
-30.27%-145.27%-330.78%-578.00%-
Upgrade
Profit Margin
-25.26%-146.43%-158.39%-575.12%-
Upgrade
Free Cash Flow Margin
-32.11%-116.32%-118.10%-440.51%-
Upgrade
EBITDA
-24.94-93.97-52.64-119.54-82.84
Upgrade
EBITDA Margin
-29.40%-143.98%-150.85%-576.09%-
Upgrade
Depreciation & Amortization
0.740.840.780.40.17
Upgrade
EBIT
-25.67-94.81-53.42-119.94-83
Upgrade
EBIT Margin
-30.27%-145.27%-153.09%-578.00%-
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).